tiprankstipranks
Trending News
More News >
Barinthus Biotherapeutics Plc (BRNS)
:BRNS
Advertisement

Barinthus Biotherapeutics (BRNS) Stock Statistics & Valuation Metrics

Compare
97 Followers

Total Valuation

Barinthus Biotherapeutics has a market cap or net worth of $47.61M. The enterprise value is -$38.17M.
Market Cap$47.61M
Enterprise Value-$38.17M

Share Statistics

Barinthus Biotherapeutics has 40,339,394 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40,339,394
Owned by Insiders
Owned by Institutions

Financial Efficiency

Barinthus Biotherapeutics’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -46.33%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-46.33%
Return on Capital Employed (ROCE)-0.47
Revenue Per Employee142.56K
Profits Per Employee-582.70K
Employee Count105
Asset Turnover0.09
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Barinthus Biotherapeutics is ―. Barinthus Biotherapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value0.37
Price to FCF
Price to Operating Cash Flow-1.61
PEG Ratio

Income Statement

In the last 12 months, Barinthus Biotherapeutics had revenue of 14.97M and earned -61.07M in profits. Earnings per share was -1.55.
Revenue14.97M
Gross Profit14.97M
Operating Income-67.97M
Pretax Income-61.23M
Net Income-61.07M
EBITDA-55.37M
Earnings Per Share (EPS)-1.55

Cash Flow

In the last 12 months, operating cash flow was -38.12M and capital expenditures -428.84K, giving a free cash flow of -38.54M billion.
Operating Cash Flow-38.12M
Free Cash Flow-38.54M
Free Cash Flow per Share-0.96

Dividends & Yields

Barinthus Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.68
52-Week Price Change-4.84%
50-Day Moving Average1.21
200-Day Moving Average1.04
Relative Strength Index (RSI)45.43
Average Volume (3m)2.57M

Important Dates

Barinthus Biotherapeutics upcoming earnings date is Nov 6, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date

Financial Position

Barinthus Biotherapeutics as a current ratio of 8.03, with Debt / Equity ratio of 10.32%
Current Ratio8.03
Quick Ratio8.03
Debt to Market Cap0.04
Net Debt to EBITDA1.78
Interest Coverage Ratio-1.28K

Taxes

In the past 12 months, Barinthus Biotherapeutics has paid -44.00K in taxes.
Income Tax-44.00K
Effective Tax Rate<0.01

Enterprise Valuation

Barinthus Biotherapeutics EV to EBITDA ratio is 0.92, with an EV/FCF ratio of 1.71.
EV to Sales-3.41
EV to EBITDA0.92
EV to Free Cash Flow1.71
EV to Operating Cash Flow1.76

Balance Sheet

Barinthus Biotherapeutics has $86.26M in cash and marketable securities with $11.99M in debt, giving a net cash position of -$74.27M billion.
Cash & Marketable Securities$86.26M
Total Debt$11.99M
Net Cash-$74.27M
Net Cash Per Share-$1.84
Tangible Book Value Per Share$2.75

Margins

Gross margin is 259.85%, with operating margin of -454.07%, and net profit margin of -408.00%.
Gross Margin259.85%
Operating Margin-454.07%
Pretax Margin-409.03%
Net Profit Margin-408.00%
EBITDA Margin-369.92%
EBIT Margin-408.67%

Analyst Forecast

The average price target for Barinthus Biotherapeutics is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.00
Price Target Upside154.24% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast-5.42%

Scores

Smart Score5
AI Score46
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis